Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $24.3100 (1.76%) ($24.3100 - $24.3100) on Mon. Dec. 21, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.87% (three month average) | RSI | 61 | Latest Price | $24.3100(1.76%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 0.4% a day on average for past five trading days. | Weekly Trend | FOLD advances 2.8% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Rotation from value to growth for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(53%) IWO(50%) XBI(48%) IWM(46%) IWC(44%) | Factors Impacting FOLD price | FOLD will decline at least -1.435% in a week (0% probabilities). VIXM(-28%) VXX(-13%) UUP(-11%) UNG(-6%) TLT(-1%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.435% (StdDev 2.87%) | Hourly BBV | 2.1 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | 5 Day Moving Average | $23.98(1.38%) | 10 Day Moving Average | $23.29(4.38%) | 20 Day Moving Average | $23.04(5.51%) | To recent high | 0% | To recent low | 82.6% | Market Cap | $6.277b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |